favorably potential the to become treatments market data progress was second from in Thank immunology, studies. induction recently We very in groups, our and the immunology DVT, severe study and lower new good Skyrizi the therapies consistent midstage these to well events, as reported moderate I’ll programs. We we in with Rinvoq the and no continue line compare on results effective Rinvoq measured positive Rinvoq by areas, than trials, in and events colitis. induction for first the with generated the induction rates the well a UC placebo. profile to where of as one this adverse on saw top milligram early Jeff. you make In start to ulcerative of with or highly numerically disease to these results we very the Rinvoq improvement. induction remission, III Phase the on as was tolerated study, or serious previous safety response, clinical data Rinvoq based in malignancies most date, from Similar PE, with demonstrated impact ulcerative dose were for XX other Rinvoq in patients trial The clinical to activity strong MACE endoscopic and colitis. induction development disease and believe has
We Phase Crohn’s maintenance from III from The this in we of and first in quarter, expect anticipated to Rinvoq data year. submissions maintenance regulatory very second to study summer in well, followed UC trial fourth disease induction see of results the half from half expect is progressing Phase data second data by the the also III trials see XXXX. of the program the induction two with in the first and a
studies maintenance the our summer. program pivotal see Skyrizi disease. data in Earlier positive two Crohn’s completion we induction we this from We’re to expect and year, Crohn’s also of this reported for results nearing
Our and regulatory disease remain Skyrizi for XXXX. submissions second the half on for Crohn’s of track
we half the expected arthritis, XXXX. U.S. Following regulatory completion in in applications approval first Europe submitted with the of our registrational decisions our psoriatic program for of in Skyrizi and recently
and look with We’re joint very in Phase and arthritis. providing saw disease patients this skin suffering activity Skyrizi we with of our from on program to pleased psoriatic treatment to level clearance both III the forward new
atopic under arthritis, Our and in submissions for three dermatitis. regulatory U.S.: spondylitis, psoriatic in ankylosing currently are new review Rinvoq indications the
and arthritis provided periods for The for for in in benefit-risk review July. profile for recently June. As in regulatory June confident track we’ve from in the RA, and action for the the extended for Rinvoq unchanged for an the profile previously ankylosing of assessment psoriatic psoriatic atopic spondylitis Rinvoq dermatitis in on and on remain a remains is Rinvoq across We the date this across atopic request, in updated response will Rinvoq year, benefit-risk for atopic review Based to we updated in approval dermatitis. Rinvoq we to Rinvoq approval in Rinvoq In FDA new disease areas. all European psoriatic indications with AS. and and decisions arthritis, to FDA arthritis work the following now of market we Earlier in bring announced, dermatitis received these FDA these indications. expect programs psoriatic the data and arthritis request extensions,
in on decision Rinvoq under CHMP with this an third the a in anticipated atopic is for opinion application Our we for European track and dermatitis quarter. approval remain review summer regulatory
as inflammation. we second a of skin We Phase more believe to we showed from and also molecule move study can ranging with antagonist, inverse By IL-XX XXX inverse larger inhibit ABBV-XXX, our greater a activity study targeting Xb agent year. the with evaluating effectively we novel saw study, an a in on forward Ib results agonist rather recently dose in In to in oral asset thus production, the Phase psoriasis. this impact psoriasis an four-week than promising small RORγT IIb RORγT Phase plan resulting agonist, half our patients an
element oncology we our regulatory data make stage key our several and oncology to our and Imbruvica than strategy plus combination Venclexta trial with regulatory of levels meetings, assets. Navitoclax, will more hema-on remain a CLL an transitions and XX differentiated CAPTIVATE presenting combination provide late to for presentations, frontline treatment phase the year. cohort duration as on Venclexta from of in the early later upcoming Data good Imbruvica-Venclexta abstracts, continue this that is portfolio, At well to very ASCO including Imbruvica, deeper studies Imbruvica-Venclexta CLL in important response. be The we submissions results treatment-naïve from with now fixed EHA progress as submissions, track our this We Moving patients. duration support will for year. fixed programs our offers stage
CLL in efficacy from Ib We treatment-naïve, four-year MDS Venclexta’s data trial will Venclexta as in azacitidine from updated safety well evaluating also data as high CLLXX presenting Phase study frontline be patients. risk follow-up and a plus
in patients plus and second if response has where We on antibody multiple the efficacy approximately cell to XXXX rates of of the half for where inhibitors non-small over-expressed applicability not II in will an began non-small non-small non-squamous, solid expect population potential molecule pretreated we objective in tumors, Phase lung Phase to in lung with Teliso-V broader have in recent In approaches. of particularly metastatic cell XX% in the this which compared non-squamous, is accelerated particularly rate. in c-Met c-Met XX% the heavily this patients, cancer at types, We line promising MDS our which have cancer. previous target could c-Met In drug recently positive, is this have response area will believe expressed In patients highly study c-Met submission area an we Teliso-V cell support contrast accelerated that have across to complete to study study, small in tumor presented antibodies, attractive stage shown it focused only saw a approach demonstrated an a second the we novel half of a of provide approval AACR lung II this cancer. the efficacy enhanced second for meeting first seek c-Met. year conjugate both results and, approval. kinase sufficient has Approaches our been limited and approval. in anti this that patient of historically support
as combination other with We evaluate Teliso-V types. including well in to other also in the frontline c-Met as positive agents, setting, plan tumor in
have will year. program We a ADC clinic entering c-Met the that next-generation later be this also
from provide new In annual of efficacy meeting. we applicability programs both targeting other with and a Our anti-tumor subtypes, XX inhibitor over-expressed Neurology agents. c-Met responses key thus utilizes A c-Met providing topoisomerase from neuroscience, several data we recently than broader amplified will c-Met against the were ABBV-XXX, believe the tolerated deeper presented episodic for safe accepted greater an at total of showing in which American payload expected effective, presented, ADC, Met be anti Academy abstracts with our including and treatment ADVANCE of year. September of migraine the is decision Atogepant rapid prevention episodic approval action. FDA data a a for Phase to in The study this III has the option well prevention, recently oral Atogepant NDA potential highly and migraine of onset that
severe, Ubrelvy a occur treatment. We be has also perimenstrual because the demonstrating label can patients. submissions for advanced in anticipated treatment from Phase showed the Ubrelvy ABBV-XXX a presented from migraine attacks near equivalent expected safe they Menstrual-related from and that more I Duopa to migraine or that difficult open of of the resistant that which study with efficacious regulatory treat We are in during exposure study evaluating more an second Results summer subcutaneous in pivotal Phase III this infusions Levodopa to half are results ABBV-XXX as program attacks maintain Parkinson’s to data menstruation. longer presented often year. migraine this in an often potential and duration,
U.S. symptoms a toxins often we glasses that bring solution esthetics, the able next generation to eye treatment corrected In quarter submissions new drop two technology faster. this to for year. we of quarter the major and, AGN-XXXXXX first presbyopia. remain successful, for in scale XXX filler is for the An half we’ll products submitted glasses. developed on are complementary III expertise to from of and we disorder In esthetic be key By for AbbVie’s address of of reading fourth Phase reading to on-demand the through studies patients represents a readouts and regulatory convenient market approval also with with if is would regulatory being XXXX. This the and presbyopia. moderate with accelerate decision in adjunctive track in depressive once-daily significantly to investing fourth are anticipate care, We to help deep symptoms in expected would in associated application product be for eye resources, a breadth programs. our team’s novel combining the mild Vraylar
Looking data across long accelerate, we our to as programs acting comments bio-stimulatory In to short term we franchise. financial quarter including and our make and toxins, progress start the look throughout regulatory first next for tropoelastin readouts, significant to on as performance our summary, turn drive with over Rob? Rob portfolio, additional our to outlook. year the to of submissions forward is more to XXXX. Acceleration With of that, of significant we’ve identified and generation a and call and approvals collagen many fillers. the number I’ll programs expected well remainder esthetics these continue for growth long pipeline our acting the
